PleoPharma Raises $36M in Series B to Advance Cannabis-Related Therapies

Deal Summary

PleoPharma, a clinical-stage company developing treatments for cannabis-related neuropsych and addiction issues, closed a $36M Series B financing. The round was undisclosed as to backers and will support clinical development efforts under CEO Ginger Constantine, MD.